Neurology Clinical Trials

A research study for cognitive testing and imaging in participants with Frontotemporal Dementia (FTD). All study procedures will be conducted at the IU Health Neuroscience Center at no cost to you. There is no study medication in this clinical trial.

You may be eligible is you have a diagnosis of Frontotemporal Dementia and are able to undergo an MRI (do not have a pacemaker or severe claustrophobia).

For more information, email us at neuroct@iu.edu or call 317-963-4823.

Faculty: David Clark, MD

The Indiana Biobank Discovery Network is seeking volunteers to donate blood and a CSF sample. The purpose of the Indiana Biomarker Discovery Study project is to enable discovery of diagnostic tools and treatments for Alzheimer’s disease and other neurological disorders. There is no medication associated with this research study. Participants may or may not have a diagnosis of Alzheimer’s disease and may still participate with no concerns about their memory. The study is also looking for participants who have progressive supranuclear palsy (PSP).

All study procedures will be conducted at the IU Health Neuroscience Center at no cost to you. You may be eligible if you are between the ages of 40-85, and able to undergo an MRI.

For more information, email neuroct@iu.edu or call 317-963-4823.

Faculty: Jeff Dage, PhD

A research study for participants with Alzheimer’s disease to study the effect of niacin (vitamin B3) on cognition.  All study procedures will be conducted at the IU Health Neuroscience Center at no cost to you. Participants will take study medication niacin (vitamin B3) or placebo once daily for approximately 60 days and return to the research center at Day 30 and Day 60 for follow-up, including a lumbar puncture for cerebrospinal fluid (CSF) collection.

You may be eligible if you are ages 60 to 85, have a diagnosis of Alzheimer’s disease and have a study partner that can attend study appointments with you. Please note, you will be asked to not take multivitamins or supplements (including Liquid IV and energy drinks) containing niacin/vitamin B3 for 90 days during your participation in the study.

For more information, email neuroct@iu.edu or call 317-963-4823.

Faculty: Jared Brosch, MD

A research study to form a group of participants with Down Syndrome interested in research treatments in the future for dementia. All study procedures will be conducted at the IU Health Neuroscience Center at no cost to you. There is no study medication in this research study. Visits will consist of yearly questionnaires to follow participants over a period of time.

You may be eligible if you have Down Syndrome, are able to undergo an MRI (do not have a pacemaker or severe claustrophobia) and are between the ages of 30-55.

For more information, email neuroct@iu.edu or call 317-963-4823.

Faculty: David Clark, MD and Jill Fodstad, PhD

Clinical Trial Website

A registry research study for participants with Huntington’s disease. All study procedures will be conducted at the IU Health Neuroscience Center at no cost to you. There is no study medication in this research study. Visits will consist of yearly questionnaires to follow participants over a period of time.

You may be eligible to participate if you are 18 years of age or older and have a confirmed genetic mutation for Huntington’s disease.

For more information, email neuroct@iu.edu or call 317-963-4823.

Faculty: Christopher James, MD

A research study of study medication Votoplam to reduce the level of mutant Huntington protein and symptoms of disease in those with Huntington’s disease. All study procedures will be conducted at the IU Health Neuroscience Center at no cost to you. Participants will take the study medication or placebo, orally, daily, at home. Participants will then return to the Neuroscience Center every three months for up to three years for monitoring and functional testing.

You may be eligible if you are between the ages of 21 to 70, have a genetically confirmed diagnosis of Huntington’s disease and be able to swallow oral tablets.

For more information, email neuroct@iu.edu or call 317-963-4823.

Faculty: Christopher James, MD

A research study to collect blood or saliva samples from participants with Parkinson’s disease to learn if they have a genetic variant causing Parkinson’s disease. All study procedures will be conducted at the IU Health Neuroscience Center at no cost to you. There is no study medication in this research study. Participants will sign a consent and provide a saliva sample either in clinic or at home, and receive a free genetic disclosure session after results are received.

You may be eligible if you are over the age of 18, have a diagnosis of Parkinson’s disease and do not have an active cancer diagnosis.

For more information, email neuroct@iu.edu or call 317-963-4823.

Faculty: Elizabeth Zauber, MD

A research study to evaluate study the aspirin or Plavix in those with a diagnosis of stroke and atrial fibrillation. Participants can be enrolled while admitted to the hospital for a stroke or up to six months after experiencing a stroke. After leaving the hospital, participants will take aspirin or Plavix daily at home and return to the research center for follow-up.

You may be eligible if you are over 18 years of age, have a diagnosis of stroke, and have atrial fibrillation.

For more information, email neuroct@iu.edu or call 317-963-4823.

Faculty: Lisa Nobel, MD, PhD

A research study to follow participants with recent stroke over four years for cognitive and functional changes. Participants are consented within six weeks after a stroke and complete a one time blood draw with cognitive testing every six months. Many assessments are completed over the phone. Any onsite assessment will be completed at the IU Health Neuroscience Center at no cost to you. No medication is associated with this research study.

You may be eligible if you are over the age of 18, were admitted to the hospital with a diagnosis of a stroke and have no history of dementia.

For more information, email neuroct@iu.edu or call 317-963-4823.

Faculty: Jason Mackey, MD

A research study to evaluate study medication Milvexian after a stroke, to try to prevent future strokes. Participants will be enrolled while admitted to the hospital for a stroke. After leaving the hospital, participants will take the study medication or placebo orally, daily at home. Participants will then return to the IU Health Neuroscience Center for safety evaluation and follow-up every three months for approximately two-and-a-half years.

You may be eligible if you are over 40 years of age, have a diagnosis of stroke and do not have a history of increased bleeding risk.

For more information, email neuroct@iu.edu or call 317-963-4823.

Faculty: Ann Jones, MD

A research study to evaluate study the delivery of small electrical impulses after a stroke, to try to improve upper extremity functioning. Participants will be enrolled while admitted to the hospital for a stroke. After leaving the hospital, participants will return to the research center after three months for physical testing. Participants will also receive phone calls from the study team in between discharge and the three month mark to check in.

You may be eligible if you are over 18 years of age, have a diagnosis of stroke, and have decreased function in your arms due to your stroke.

For more information, email neuroct@iu.edu or call 317-963-4823.

Faculty: Ann Jones, MD

A research study for participants with Amyotrophic Lateral Sclerosis (ALS, or Lou Gehrig’s disease) or participants with a first degree relative with ALS to study the genetics and biomarkers of the disease through blood and cerebrospinal fluid (CSF) collection. All study procedures will be conducted at the IU Health Neuroscience Center at no cost to you. Study medication could be an oral medication taken daily at home, or a subcutaneous shot.

You may be eligible if you are over the age of 18, have a diagnosis of ALS or are a first-degree relative of someone with ALS, and are willing to undergo a blood draw and optional lumbar puncture.

For more information, email neuroct@iu.edu or call 317-963-4823.

Faculty: Cynthia Bodkin, MD

 

A registry research study for participants with Pompe disease. There is no study medication for this trial. Participants will answer questions and be followed clinically by the research team to further understand Pompe disease and treatments. All study procedures will be conducted at the IU Health Neuroscience Center. Participants will be followed for up to five years.

You may be eligible to participate if you are over the age of 18, have a diagnosis of Pompe disease and receive medical therapy, and are not currently receiving a study medication in another trial for Pompe disease.

For more information, email neuroct@iu.edu or call 317-963-4823.

Faculty: Cynthia Bodkin, MD

A research study to evaluate DYNE101 to reduce disease symptoms and progression in participants with Myotonic Dystrophy Type 1. All study procedures will be conducted at the IU Health Neuroscience Center or Methodist Hospital. Participants will have an IV infusion of DYNE101 or placebo approximately every eight weeks. After 12 months of treatment, participants may receive active study medications (no placebo group).

You may be eligible if you are at least 18 years of age, have a confirmed genetic diagnosis of Myotonic Dystrophy Type 1, do not have a heart arrhythmia (pacemaker or defibrillator are allowed) and are not currently taking GLP-1 medications.

For more information, email neuroct@iu.edu or call 317-963-4823.

Faculty: Adam Comer, MD

A research study for participants with ALS. This research study has different study medication options available for participants with ALS. All study procedures will be conducted at the IU Health Neuroscience Center at no cost to you. Study medication could be an oral medication taken daily at home, or a subcutaneous shot.

You may be eligible if you are over the age of 18, have an onset of ALS symptoms within the last 36 months and are able to swallow pills and liquids for the duration of the trial.

For more information, email neuroct@iu.edu or call 317-963-4823.

Faculty: Cynthia Bodkin, MD

A research study to evaluate CAR T-cell therapy KYV-101 to achieve long-term remission in participants with generalized Myasthenia Gravis. All study procedures will be conducted at the IU Health Neuroscience Center or Methodist Hospital. Please note, the trial requires a 10-day inpatient stay and participants will be required to stay within a one-hour radius of the hospital for up to 28 days. Participants will receive a one-time dose of KYV-101 in the hospital via an IV.

You may be eligible if you are between the ages of 18-75, have generalized Myasthenia Gravis (gMG) with the presence of autosntibodies (AChR or MuSK), have failed at least two prior treatments for gMG, and have not used IVIg, PLEX, or Rituximab recently for treatment of your gMG.

For more information, email neuroct@iu.edu or call 317-963-4823.

Faculty: Alex Barboi, MD

A research study for participants with Postural Orthostatic Tachycardia Syndrome (POTS) to improve symptoms of high heart rate and low blood pressure upon standing. All study procedures will be conducted at the IU Health Neuroscience Center at no cost to you. Participants will receive three subcutaneous injections of study medication or placebo, at two visits approximately one week apart. Participants will return to the research center every few weeks for two months in follow-up.

You may be eligible if you are ages 18 to 55 with a diagnosis of POTS, and do not have a history of or take medication for high blood pressure.

For more information, email neuroct@iu.edu or call 317-963-4823.

Faculty: Alex Barboi, MD

A research study that evaluates Ibudilast to reduce inflammation in participants with ALS. All study procedures will be conducted at the IU Health Neuroscience Center at no cost to you. Participants will take the study medication or placebo orally, daily at home and return to the research center for follow-up. Some visits can be complete over the phone.

You may be eligible if you are ages 18- 80, have a diagnosis of ALS and are able to swallow capsules.

For more information, email neuroct@iu.edu or call 317-963-4823.

Faculty: Cynthia Bodkin, MD

An open-label clinical trial for participants with recurrent glioblastoma, for use of oral Niraparib in conjunction with radiation. All study procedures will be conducted at the IU Health Neuroscience Center or Methodist Hospital. Some participants will not receive the Niraparib and will be followed as they receive standard therapies. Participants will be seen at the Neuroscience Center approximately every three weeks over the course of eight months for treatment and follow-up.

You may be eligible if you are over the age of 18 and have a glioblastoma brain tumor.

For more information, email neuroct@iu.edu or call 317-963-4823.

Faculty: Kathryn Nevel, MD 

A research study for medications ERAS-801 in combination with ABBV-155 or ABBV-637 for participants with glioblastoma. All study procedures will be conducted at the IU Health Neuroscience Center. Participants will take the ERAS-801 medication orally and receive the ABBV-155 or ABBV-637 intravenously in the clinical research center monthly.  

You may be eligible if you are over the age of 18 and have measurable glioblastoma tumor.

For more information, email neuroct@iu.edu or call 317-963-4823.

Faculty: Kathryn Nevel, MD

An open-label clinical trial for participants with Grade 1, 2 or 3 meningioma, for the use of intravenous LUDOTATATE. All study procedures will be conducted at the IU Health Neuroscience Center. Some participants will not receive LUDOTATATE and will continue to receive standard of care therapies. Participants will be seen at the Neuroscience Center approximately once per month for six months and followed for up to two years.

You may be eligible if you are over the age of 18 and have a diagnosis of meningioma with recent progression.

For more information, email neuroct@iu.edu or call 317-963-4823.

Faculty: Kathryn Nevel, MD

An open-label clinical trial for participants with recurrent glioblastoma, for use of the Sonocloud-9 device in conjunction with chemotherapy to better distribute medication to the tumor bed. All study procedures will be conducted at the IU Health Neuroscience Center or Methodist Hospital. Participants will undergo standard tumor resection, and those chosen to receive the Sonocloud-9 device in the trial will have it implanted at the time of surgery.  Some participants will not receive the Sonocloud-9 device and will be followed as they receive standard therapies. Participants will be seen at the Neuroscience Center approximately every three weeks over the course of six months for treatment and follow-up.

You may be eligible if you are over the age of 18 and have a glioblastoma brain tumor, and are able to undergo surgery for partial removal of your tumor and placement of the Sonocloud-9 device.

For more information, email neuroct@iu.edu or call 317-963-4823.

Faculty: Kathryn Nevel, MD 

A research study on the timeline of PLEX vs. high dose corticosteroid administration in participants with transverse myelitis or optic neuritis. Most study procedures will be conducted at the IU Health Neuroscience Center. Participants will consent to be followed after receiving PLEX and/or high dose corticosteroids, while completing assessments to evaluate changes in vision or movement. Participants will return to the Neuroscience Center for evaluation approximately every three months for one year.

You may be eligible if you received a recent diagnosis of optic neuritis or transverse myelitis, are over 18 years of age and are not pregnant.

For more information, email neuroct@iu.edu or call 317-963-4823.

Faculty: Devin Mackay, MD